April 26, 2025
2 min watch
NATIONAL HARBOR, Md. — On this video at Weight problems Medication 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his speak on anti-obesity medicines within the pipeline.
There may be an “unbelievable variety of anti-obesity medication in growth,” together with GLP-1 receptor agonists with different incretins and urge for food suppressants, Bays, chief science officer and president-elect of the Weight problems Medication Affiliation, advised Healio.
Bays, who can be the medical director and president of the Louisville Metabolic and Atherosclerosis Analysis Middle, additionally mentioned muscle sparing with anti-obesity medication, how these medication are accepted and the necessity for higher entry.
“It has simply been an thrilling convention to date,” he mentioned.
Reference:
- Bays HE. Investigational anti-obesity medicines within the pipeline. Offered at: Weight problems Medication 2025. April 23-27, 2025; Nationwide Harber, Md.
For extra data:
Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, could be reached at primarycare@healio.com.
